Johnson And Johnson Balances Mental Health Push With Mixed Pipeline Outlook
Johnson & Johnson (NYSE:JNJ) has launched its global "Generation Fine" campaign to address depression care and improve patient conversations. The company reported new FDA approvals and positive Phase 3 data in immunology and neuropsychiatry, alongside progress on its OTTAVA robotic surgery platform. JNJ outlined an accelerated global registration plan for JNJ-1900 in head and neck cancer. The dual target antibody JNJ-4804 for inflammatory bowel disease did not meet its main Phase 2b...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
